For example, PARPis and ICB have not produced dramatic responses in patients with BRCA1mut- and HR-deficient high-grade serous ovarian cancer, as PARPis can mediate immune resistance and tumor progression by upregulating VEGF-A. Here, VEGFA is linked to ovarian serous adenocarcinoma.